Research Synthesis: Urolithin A Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Repair the truncated Abstract sentence and the truncated Results paragraph; render complete sentences throughout.
2. Replace every 'Additional corpus sources included animal/preclinical evidence;' placeholder with the actual study name(s) so that source attribution is auditable at the sentence level.
3. Reconcile the Singh 2022 representative-statistic assignment: either cite the headline ~12% strength improvement with the supporting p-value range, or label the P < 0.0001 statistic with the specific biomarker endpoint it belongs to.
4. Fix the duplicated 'immune and inflammation' row in the Boundary-Condition Matrix and reconcile the cardiometabolic direct/indirect counts against the Results summary tables.
5. Recode Wilhelmsen 2025 direction to align with the positive glucose-uptake / myostatin-suppression results in the cited excerpt, or explicitly justify the negative coding with a specific endpoint.
6. Recode or reframe Acevedo 2025 to reflect the positive Yo-Yo IRT1 result (p = 0.048) or justify the unclear label with the specific endpoints that are null.
7. Drop or substantially reframe the severity-4 'null vs positive' disagreements that pair Mirzaei 2026 (canine spermatozoa) with human supplement-label, chronobiology, or food-chemistry studies; these are not same-outcome cross-study tensions and should not appear in the cross-study disagreement map as directional conflicts.
8. Re-examine the outcome-class assignments for Bai 2026 and Ryu 2024 and move them to outcome classes that match their primary endpoints (immune/bone biology vs hepatocyte ER stress), so the Findings Map does not inflate skeletal evidence.
9. Standardize 'Urolithin A' capitalization across the manuscript.

Major issues

• The Abstract and several prose paragraphs contain truncated sentences (e.g. 'highly trained male runners in the indirect observational study Whitfield 2025 (NCT04783207) showed mostly non-significant performance end-points (e.', 'Endogenous urolithin A.'), indicating a rendering/extraction defect that breaks readability and traceability.
• Multiple Evidence Snapshot bullets and Results paragraphs include repeated boilerplate 'Additional corpus sources included animal/preclinical evidence;' strings where actual study names should appear, materially degrading source traceability and auditability.
• The Evidence Snapshot lists Singh 2022 with 'representative statistic=P < 0.0001' while the source bundle quotes show Singh 2022's headline result as ~12% strength improvement with per-endpoint p-values around 0.027–0.029, not P < 0.0001. The representative-statistic assignment for Singh 2022 is inconsistent with the cited primary trial result.
• The Boundary-Condition Matrix in 'What This Synthesis Adds' lists 'immune and inflammation' twice with conflicting direct-source counts (0/3 vs 2/3), and the Body-Cardiometabolic cells are misaligned with the Results tables that report n=5 for cardiometabolic. The matrix contains an internal inconsistency.
• Wilhelmsen 2025 is coded direction=negative in the Findings Map but described in prose as showing 'positive mechanistic effects on glucose uptake' and the bundle excerpt reports significant positive effects (21% basal, 24% insulin-stimulated glucose uptake, P < 0.05/<0.01). The directional coding contradicts the source content.
• Acevedo 2025 is classified as 'Deficiency Prevalence' (n=1 outcome class) and tagged direction=unclear in the Findings Map, but the bundle quotes 'Yo-Yo IRT1 performance Δ = +239 m, p = 0.048' (a clearly positive performance effect). Coded direction conflicts with primary endpoint.
• The Mirzaei 2026 canine spermatozoa study is repeatedly used as comparator for human context 'contextual adjacent evidence' tensions (severity-4 disagreements vs Sandalova 2024, Kuatov 2024, Pidgeon 2025, E 2025, Houssein-Zadeh 2025, Ma 2026, Francisco 2026). These are not same-outcome comparisons and the severity-4 'partial conflict' framing between a canine in vitro sperm study and a supplement-label assay or a chronobiology cell study is methodologically inappropriate as a directional conflict.

Minor issues

• The keyword 'Urolithin A' is inconsistently cased across the manuscript ('Urolithin A' vs 'urolithin A' vs 'urolithin a'); standardize for publication.
• Dominguez-Lopez 2025 is coded direction=positive in the Findings Map but the Results narrative describes its urolithin-A-specific signal as 'directionally null at the urolithin A metabolite level for hard CVD endpoints.' Coding and prose diverge.
• Bai 2026 outcome class is 'Immune and Inflammation' in the Findings Map but the bundle title and excerpt frame it as osteogenic/bone fracture healing; outcome class assignment is contestable.
• Ryu 2024 is classified under 'Skeletal, Fracture, and Bone' but the source content is hepatocyte ER stress / MAM calcium handling; the outcome class assignment is questionable and inflates the skeletal evidence base.
• The search corpus uses 'older adults' as the population anchor but only Liu 2022 enrolled adults 65–90; the manuscript repeatedly generalizes Singh 2022's middle-aged cohort into 'aging' claims without explicit age-bound qualification.
• Repeated boilerplate phrases ('limited corpus depth in this outcome class', 'hypothesis-generating', 'mechanistic plausibility coexists with mixed or sparse human-RCT evidence') appear verbatim across many rows; this dilutes the synthesis voice and obscures per-class substance.
• The 'next-study design recommendation' specifies ≥200 participants/arm and ≥12-month follow-up without tying the threshold to a power calculation or to the specific endpoint gap being closed; it reads as generic rather than calibrated.

Reviewer note

This is a research-synthesis manuscript on urolithin A effects across 38 sources and seven outcome classes. It has the structural ingredients of a gatekeeper-tier artefact — explicit Methods/Search Summary, a quantitative Findings Map with per-source direction and tier, an Evidence Snapshot, a Cross-Domain Synthesis section, a Boundary-Condition Matrix, an Evidence-Gap Priority table, and a Next-Study Design Recommendation. The integration logic across direct RCT vs indirect mechanistic evidence is sound in outline, and the conservatism about clinical translation is appropriate. However, the manuscript has several rendering and consistency defects that fall below the bar for acceptance. The Abstract and Results sections contain truncated sentences; many 'Evidence Snapshot' and Results paragraphs substitute a repeated boilerplate ('Additional corpus sources included animal/preclinical evidence;') for actual study names, breaking traceability. Internally, there are clear inconsistencies between the Findings Map direction coding and the source content for Wilhelmsen 2025 (coded negative, but the cited excerpt shows positive glucose-uptake results) and Acevedo 2025 (coded unclear, but the cited primary endpoint is positive at p = 0.048). The Singh 2022 representative statistic of P < 0.0001 is not the trial's headline endpoint per the cited excerpt; the Boundary-Condition Matrix lists immune and inflammation twice with conflicting direct-source counts; and the severity-4 disagreement map pairs a canine spermatozoa study with human supplement-label, chronobiology, and food-chemistry studies, which are not same-outcome tensions and should not be coded as directional conflicts. On the positive side, the cross-domain synthesis is intellectually honest — it surfaces the direct/indirect gap, the population specificity (elite runners, academy athletes, middle-aged adults, older adults), the ceiling-effect interpretation for trained runners, and the need for hard-endpoint RCTs before clinical claims. The limitations section is substantive and ties the conclusion to specific missing trials (mortality, hard cardiovascular endpoints, frailty cohorts). The gaps and next-study recommendation are concrete, even if generic on sample size. The recommendation is revise. With bounded edits — repairing truncated text, replacing boilerplate placeholders with real citations, recoding the inconsistent direction labels, fixing the duplicated Matrix row, and reframing the canine-sperm cross-study tensions — the manuscript can move into accept territory. As submitted, the traceability defects and internal inconsistencies are material enough that the bounded conclusion is only partially supported by the cited evidence.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis